Get the Stockscreener App
0.672
7.58%
-0.0551
After Hours:
.68
0.008
+1.19%
Renovaro Inc stock is traded at $0.672, with a volume of 238.13K.
It is down -7.58% in the last 24 hours and down -32.80% over the past month.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
See More
Previous Close:
$0.7271
Open:
$0.74
24h Volume:
238.13K
Relative Volume:
0.22
Market Cap:
$106.66M
Revenue:
-
Net Income/Loss:
$-41.23M
P/E Ratio:
-0.96
EPS:
-0.7
Net Cash Flow:
$-11.54M
1W Performance:
-12.18%
1M Performance:
-32.80%
6M Performance:
+10.13%
1Y Performance:
-84.44%
1-Day Range:
$0.672
$0.747
1-Week Range:
$0.67
$0.8035
52-Week Range:
$0.395
$4.36
Renovaro Inc Stock (RENB) Company Profile
Name
Renovaro Inc
Sector
Industry
Phone
45 39179840
Address
CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES
Compare RENB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RENB
Renovaro Inc
|
0.672 | 106.66M | 0 | -41.23M | -11.54M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Renovaro Inc Stock (RENB) Latest News
Renovaro Inc (RENB) Stock: From Low to High in 52 Weeks - The InvestChronicle
Renovaro Inc. (NASDAQ:RENB) Stock Holdings Increased by JPMorgan Chase & Co. - Defense World
Quarterly Snapshot: Quick and Current Ratios for Renovaro Inc (RENB) - The Dwinnex
Renovaro Inc (RENB)’s results reveal risk - US Post News
Barclays PLC Has $34,000 Stock Position in Renovaro Inc. (NASDAQ:RENB) - Defense World
Short Interest in Renovaro Inc. (NASDAQ:RENB) Rises By 30.7% - MarketBeat
Renovaro Inc. appoints new CFO Nathen Fuentes - Investing.com India
Renovaro Inc. appoints new CFO Nathen Fuentes By Investing.com - Investing.com South Africa
Geode Capital Management LLC Decreases Stake in Renovaro Inc. (NASDAQ:RENB) - Defense World
Renovaro To Buy Predictive Oncology in All-Stock Deal - Pulse 2.0
Renovaro Biosciences Subsidiary Appoints New CEO - MSN
Renovaro appoints Nathen Fuentes as finance chief - MSN
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Predictive Oncology Inc.POAI - The Malaysian Reserve
Renovaro Biosciences Merges with Predictive Oncology - MSN
PREDICTIVE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc.POAI - Marketscreener.com
Renovaro Inc. appoints new CEO for subsidiary By Investing.com - Investing.com Australia
Nathen Fuentes Joins Renovaro as Chief Financial Officer - citybiz
Renovaro BioSciences issues shareholder letter, provides corporate update - TipRanks
Renovaro Taps Nathen Fuentes as Finance Chief - MarketWatch
Renovaro Issues Shareholder Letter and Provides Corporate Update - The Manila Times
Renovaro Inc. appoints new CEO for subsidiary - Investing.com
Renovaro To Buy Predictive Oncology In All-Stock Deal - Pulse 2.0
Predictive Oncology shares rise 71% as takeover by Renovaro is announced - Mugglehead
Renovaro to Acquire Predictive Oncology - citybiz
M&A: Predictive Oncology to be Acquired by Renovaro - HIT Consultant
POAI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Predictive Oncology Inc. Is Fair to Shareholders - Business Wire
Renovaro to acquire Predictive Oncology in all-stock transaction - TipRanks
Renovaro to Acquire Predictive Oncology in All-Stock Transaction - The Manila Times
Predictive Oncology in Deal to Be Sold to Renovaro - MarketWatch
Renovaro to Acquire Predictive Oncology in All-Stock Transaction - Benzinga
Predictive Oncology Announces Agreement to be Acquired by Renovaro - GlobeNewswire
Predictive Oncology to Be Acquired by Renovaro in AI-Driven Cancer Research Merger - StockTitan
Renovaro Inc. entered into a binding letter of intent to acquire Predictive Oncology Inc. for for $6.2 million. - Marketscreener.com
State Street Corp Acquires 48,114 Shares of Renovaro Inc. (NASDAQ:RENB) - Defense World
Short Interest in Renovaro Inc. (NASDAQ:RENB) Expands By 27.7% - MarketBeat
Renovaro appoints new CEO for AI-driven diagnostics arm By Investing.com - Investing.com South Africa
Renovaro Inc. Appoints Maurice van Tilburg as CEO of RenovaroCube Amid Strategic Growth in AI-Powered Cancer Diagnostics - Tandav Media
Renovaro appoints new CEO for AI-driven diagnostics arm - Investing.com India
Renovaro Inc. Appoints Maurice van Tilburg as CEO of RenovaroCube to Advance AI-Powered Cancer Diagnostics - Tandav Media
Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV - The Manila Times
RENB Stock Price and Chart — NASDAQ:RENB - TradingView
Renovaro Inc. Receives Grant Approval for LUMINA Project, an AI-Powered Minimal Residual Disease Detection Platform for Lung Cancer - Nasdaq
RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program - GlobeNewswire
Renovaro regains Nasdaq compliance with bid price rule - Investing.com India
Renovaro Regains Compliance with NASDAQ Listing Requirement - The Manila Times
Renovaro Inc Stock (RENB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):